Clinicopathologic relevance of apoptotic and proliferative factors in human lung andenocarcinoma: Fas expression correlates with the histologic subtype, but not with the degree of apoptosis

Pathology Research and Practice

Volumn 198, Issue 10, 2002, Pages 645-654

  Mojtahedzadeh, Sepideh ^a   Hashimoto, Shuichi ^a   Nakashima, Yutaka ^a   Koga, Takaomi ^a   Matsuo, Yoshio ^a   Yoshino, Ichiro ^a   Sugio, Kenji ^a   Kinukawa, Naoko ^b   Sugimachi, Keizo ^a   Sueishi, Katsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Fas; Histologic heterogeneity; Ki 67; Lung adenocarcinoma; ss DNA

Indexed keywords

FAS ANTIGEN; KI 67 ANTIGEN; SINGLE STRANDED DNA; DNA;

ADULT; AGED; APOPTOSIS; CANCER CELL; CANCER CLASSIFICATION; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WORLD HEALTH ORGANIZATION; ADENOCARCINOMA; ARTICLE; CELL DIVISION; CHEMISTRY; CLASSIFICATION; ENZYME IMMUNOASSAY; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; APOPTOSIS; CELL DIVISION; DNA, NEOPLASM; DNA, SINGLE-STRANDED; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 0036456769     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1078/0344-0338-00316     Document Type: Article

References (43)

1. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F (1998) The Fas counter-attack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160: 5669-5675
2. Boussaud V, Soler P, Moreau J, Goodwin RG, Hance AJ (1998) Expression of three members of the TNF-R family of receptors (4-1BB, lymphotoxin-β receptor, and Fas) in human lung. Eur Respir J 12: 926-931
3. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759-1762
4. Ferreira CG, Tolis C, Span SW, Peters GJ, Van Lopic T, Kummer AJ, Pinedo HM, Giaccone G (2000) Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO-1) signaling pathway. Clin Cancer Res 6: 203-212
5. Fine A, Anderson NL, Rothstein TL, Williams MC, Gochuico BR (1997) Fas expression in pulmonary alveolar type II cells. Am J Physiol Lung C 273: L64-L71
6. Hellquist HB, Olejnicka B, Jadner M, Andersson T, Sederholm C (1997) Fas receptor is expressed in human lung squamous cell carcinoma, whereas bcl-2 and apoptosis are not pronounced: a preliminary report. Brit J Cancer 76: 175-179
7. KIPI Protein and Ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res 6: 4073-4081
8. Inoue S, Salah-eldin AE, Omoteyama K (2001) Apoptosis and anticancer drug resistance. [Review] Hum Cell 14: 211-221
9. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimold D, French LE, Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388: 190-195
10. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233-243
11. Izumi M, Nakanishi Y, Yoshino I, Nakashima M, Watanabe T, Hara N (2001) Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in non-small cell lung carcinoma. Cancer 92: 446-451
12. Jäckel MC, Mitteldorf CH, Schweyer S, Füzesi L (2001) Clinical relevance of Fas (APO-1/CD95) expression in laryngeal squamous cell carcinoma. Head Neck: 646-652
13. Kawahara A, Kobayashi T, Nagata S (1998) Inhibition of Fas-induced apoptosis by Bcl-2. Oncogene 17: 2549-2554
14. Koga T, Hashimoto S, Sugio K, Yoshino I, Mojtahedzadeh S, Matsuo Y, Yonemitsu Y, Sugimachi K, Sueishi K (2001) Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma. Clin Cancer Res 7: 1730-1738
15. Koga T, Hashimoto S, Sugio K, Yoshino I, Nakagawa K, Yonemitsu Y, Sugimachi K, Sueishi K (2001) Heterogeneous distribution of p53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with p53 gene mutation. Int J Cancer 95: 232-239
16. Koomägi R, Volm M (1999) Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 84: 239-243
17. Kumaki F, Matsui K, Kawai T, Ozeki Y, Yu ZX, Ferrans VJ, Travis WD (2001) Expression of matrix metallproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am J Pathol 159: 2125-2135
18. Kurokawa T, Matsuno Y, Noguchi M, Mizuno S, Shimosato Y, (1994) Surgically curable "early" adenocarcinoma in the periphery of the lung. Am J Surg Pathol 18: 431-438
19. Lee SH, Shin MS, Lee HS, Bae JH, Lee HK, Kim HS, Kim SY, Jang JJ, Joo M, Kang YK, Park WS, Park JY, Oh RR, Han SY, Lee JH, Kim, SH, Lee JY, Yoo NJ (2001) Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol 32: 250-256
20. Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, Park GS, Dong SM, Pi JH, Kim CHS, Kim SH, Lee JY, Yoo NJ (1999) Alterations of Fas (APO-1/CD95) gene in non-small cell lung cancer. Oncogene 18: 3754-3760
21. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne CH, Schmidt A, Debatin K-M, Krammer PH, Möller P (1993) Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69: 415-429
22. Mottolese M, Buglioni S, Bracalenti C, Cardarelli MA, Ciabocco L, Giannarelli D, Botti C, Natali PG, Concetti A, Venanzi FM (2000) Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer 89: 127-132
23. Nagata S, Golstein P (1995) The Fas death factor. Science 267: 1449-1456
24. Nambu Y, Hughes SJ, Rehemtulla A, Hamstra D, Orringer MB, Beer DG (1998) Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinoma. J Clin Invest 101: 1102-1110
25. Naruse I, Keino H, Kawarada Y (1994) Antibody against single-stranded DNA detects both programmed cell death and drug-induced apoptosis. Histochemistry 101: 73-78
26. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, Kondo H, Shimosato Y, (1995) Small adenocarcinoma of the lung. Cancer 75: 2844-2852
27. Norton AJ, Jordan S, Yeomans P (1994) Brief, high-temperature heat denaturation (pressure cooking): A simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 173: 371-379
28. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, Trauth BC, Posting H, Krammer PH (1992) Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: Sequence identity with the Fas antigen. J Biol Chem 267: 10709-10715
29. Owen-Schaub L, Chan H, Cusack JC, Roth J, Hill LLB (2000) Fas and Fas ligand interactions in malignant disease. [Review] Int J Oncol 17: 5-12
30. O'Connell J, Bennet MW, O'Sullivan GC, O'Callaghan J, Collins JK, Shanahan F (1992) Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege. Clin Diagn Lab Immun 6: 457-463
31. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack (1996) Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184: 1075-1082
32. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396: 699-703
33. Sato T, Irie S, Kitsuda S, Reed JC (1995) FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 268: 411-415
34. Sethi T, Rintoul RC, Moore SM, Mackinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strieter R, Haslett C (1999) Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 5: 662-668
35. Shiba M, Khono H, Kakizawa K, Lizasa T, Otsuji M, Saitoh Y, Hiroshima K, Ohwada H, Fujisawa T (2000) Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected non-small cell lung carcinoma. Cancer 89: 1457-1465
36. Shibakita M, Tachibana M, Dhar DK, Kotoh T, Kinugasa S, Kubota H, Masunaga R, Nagasue N (1999) Prognostic significance of Fas and Fas ligand expression in human esophageal cancer. Clin Cancer Res 5: 2464-2469
37. Shoji M, Dobashi Y, Morinaga S, Jiangs SX, Kameya T (1999) Tumor extension and cell proliferation in adenocarcinoma of the lung. Am J Pathol 154: 909-918
38. Symonds H, Krail L, Remington L, Saenz-Robles M, Lowe S, Jacks T, van Dyke T (1994) p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703-711
39. The Japan Lung Cancer Society (1995) General rule for clinical and pathological record of lung cancer. 4th ed. Kanehara Publications, Tokyo
40. Union Internationale Contrele Cancer (1987) TNM classification of malignant tumors, 4th ed., pp 70-73. Springer Verlag, Berlin
41. Uramoto H, Osaki T, Inoue M, Taga S, Takenoyama M, Hanagiri T, Yoshino I, Nakanishi R, Ichiyoshi Y, Yasumoto K (1999) Fas expression in non-small cell lung cancer: its prognostic effects in completely resected stage III patients. Eur J Cancer 35: 1462-1465
42. WHO (1999) Histological typing of lung and pleural tumors. Definitions and explanatory notes. 3rd ed., pp 25-47. Springer, Geneva
43. Yakirevich E, Maroun L, Cohen O, Izkah OB, Rennert G, Resnick MB (2000) Apoptosis, proliferation, and Fas (APO-1, CD95)/Fas ligand expression in medullary carcinoma of the breast. J Pathol 192: 166-173